Charity coalition pledges millions for brain disease research
Brain Tumour Research is delighted to welcome the news of a £30 million international charity coalition investment into diseases of the brain, called The Neurodegeneration Medicines Acceleration Programme.
The fund, comprising Neuro–MAP’s partners Alzheimer’s Association US, Alzheimer Research UK, Alzheimer’s Society UK, ALS Association, Michael J Fox Foundation, MND Association, MRC Technology, Northern Health Science Alliance and Parkinson’s UK, will aim to provide innovative drugs and treatments to several diseases that have a great level of unmet need.
The coalition will concentrate their investigations by looking at motor neurone disease, Parkinson’s and dementia, but their work will also inform studies into brain tumours. This research, unlike generic research into cancer, will significantly increase understanding of the brain and in particular how it copes with disease. This coalition is a great step forward for the study of neurologic diseases and will likely produce treatments for thousands of people.
However, despite these benefits we would urge the Government to ensure that there is a substantial increase in funding research into brain tumours. Despite brain tumours being the largest cancer killer of children and adults under 40, with deaths increasing over the last 10 years, research into finding a cure received only £6.8 million last year from NCRI members and overall just 1% of the national spend on cancer research. Brain tumour patients need a commitment from Government to significantly increase funding to tackle this deadly disease and we are leading the campaign for change.